BIRMEX and CIPLA sign an agreement for the supply of medicines in Mexico

Biological and Reagent Laboratories of Mexico (BIRMEX) said it signed a Strategic Association and Technology Transfer Agreement with the pharmaceutical company CIPLA from India.

The document contemplates the realization of commercial agreements to ensure the supply of oncological and retroviral drugs in our country in the short term, as well as a technology transfer scheme to ensure that BIRMEX can manufacture these products for the national supply.

CIPLA is the third largest pharmaceutical company in India, whose mission is to ensure access to high-quality medicines for the most vulnerable populations.

On behalf of the Indian company, the signing of the agreement in Mexico was attended by the senior director, head of International Business Development and Strategic Alliances, Deepak Mansukhani, and the global general counsel and executive vice president, A. S. Kumar.

The Mexican delegation was made up of authorities from the health sector, including General Jens Pedro Lohmann, general director of Birmex, an institution of the Mexican Government responsible for developing, producing, importing, and distributing vaccines and health supplies.

In April 2022, the Secretary of Foreign Affairs, Marcelo Ebrard Casaubon, made a trip to India to strengthen the Mexican health system by negotiating technology transfer agreements to produce vaccines and medicines in Mexico.